Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

NCT00360360 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Neoplasm, Unknown Primary

Interventions

DRUG: paclitaxel
DRUG: carboplatin
DRUG: bevacizumab
DRUG: erlotinib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]